i-Base

News

IAS 2015: news from the Vancouver HIV conference

START results in full, WHO recommends ART for all, HIV cure research, webcasts access, treatment as prevention in HPTN 052, HIV remission in a teenager, dispersible dolutegravir for kids, new ARVs and more…

Pipeline report 2015

Activist review of latest research into HIV, HCV and TB: drugs for adults and children, dose optimisation, diagnostics, prevention, cure and vaccines…

May/June HTB now online

Remembering Professor Martin Fisher, breaking news on the START study, reports from BHIVA, CROI and HIV & Women conferences and much more…

i-Base Q&A on the START study results

What is the START study? The START study is a large international HIV study. It looks at the risks and benefit of early HIV treatment. “Early” is defined as having a CD4 count above 500. Results are compared to a …

Breaking news: what do the START results mean for HIV positive people

At least 18 months earlier than expected, these results will change treatment guidelines globally…

March/April HTB now online

News, comment and reviews of more than 50 studies in 16 articles from CROI 2015 and 4 from the International Drug Resistance Workshop…

CROI 2015: HIV news from Seattle

All about PrEP – 6 studies plus ART prevention, 3-drug ART for PMTCT, HIV drug resistance, new drugs: TAF and maturation inhibitors, why TEMPRANO does not support early ART, weekends-off ART for some young people…

January/February HTB now online

Reports from hepatitis and TB meetings, dolutegravir in England, new London guidelines, India rejects patent for Gilead’s sofosbuvir, plus more…

Dolutegravir and Truimeq approved in England: London guidelines updated

NHS England approves dolutegravir and Triumeq and London guidelines updated for when these drugs can be prescribed…

November/December HTB now online

Stock-outs in the UK, conference reports from Glasgow, BHIVA and South Africa, plus the PROUD and IPERGAY studies and new UK data show urgency of PrEP access…

Poppers linked to permanent and serious vision loss

This is a pre-press article for the November/December edition of HTB. Simon Collins, HIV i-Base Serious vision loss linked to recreational use of poppers has been reported as a case study in this weeks issue of the Lancet. The vision …

IPERGAY PrEP study shows early efficacy in protecting gay men from HIV: all participants to switch to active drug

Simon Collins, HIV i-Base On 29 October 2014, French and Canadian researchers announced early efficacy of a PrEP study to protect gay men from catching HIV. This has led to a change in the study design. [1] The IPERGAY study is …

Q&A on PrEP in the UK and changes to the HIV PROUD study

NOTE: Please see this updated information about the PROUD results and access to PROUD in the UK. https://i-base.info/uk-proud-study-to-provide-prep-earlier-than-expected The following Q&A was produced by i-Base about PrEP in the UK including recent changes to the PROUD study. Participants in the …

UK PROUD study to provide PrEP earlier than expected: planned follow-up in this HIV prevention study to continue for two years

Important news for PrEP in the UK

Introduction to Combination Therapy (Arabic)

Please click title link for the download page.

September/October HTB now online

Reports from the 54th ICAAC and IAS 2014 conferences, newly approved drugs for HIV and hepatitis C, new UK guidelines for pregnancy and PEP, plus a potential new approach for PML…

July/August HTB now online

Ten reports from AIDS 2014, coverage from paediatric and INTEREST workshops, London guidelines, dolutegravir access in the UK, plus lots more…

HIV+ survey on a cure: please support with 10 minutes

This short survey is looking for community views from the UK and internationally to help shape future research

IAS 2014: news from Melbourne

Short reports and links to news at the 20th World AIDS Conference: cure research, PrEP (do you swallow?), pipeline report, HIV and children, HIV-related complications, activists protest Gilead’s price for sofosbuvir and global TasP…

Pipeline report 2014

Latest review of latest developments in HIV, HCV and TB: pipeline drugs, vaccines, cure strategies and diagnostics

Post navigation